Merck & Co Inc (NYSE:MRK)

82.34
Delayed Data
As of Feb 21
 -0.15 / -0.18%
Today’s Change
72.23
Today|||52-Week Range
92.64
-9.47%
Year-to-Date
Merck's Chief Digital Officer Leaves to Join Marriott
Feb 20 / MotleyFool.com - Paid Partner Content
Merck's Ebola Vaccine Approved for Use in Four African Countries
Feb 14 / MotleyFool.com - Paid Partner Content
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Feb 20 / MotleyFool.com - Paid Partner Content
Merck's Keytruda Helps Treat an Aggressive Form of Breast Cancer
Feb 12 / MotleyFool.com - Paid Partner Content
FDA Rejects New Dosing for Merck's Cancer Drug Keytruda
Feb 19 / MotleyFool.com - Paid Partner Content
Gilead Sciences Looks Ready to Outpace AbbVie
Feb 12 / MotleyFool.com - Paid Partner Content
Is Merck & Co. Stock a Buy?
Feb 19 / MotleyFool.com - Paid Partner Content
Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye
Feb 11 / MotleyFool.com - Paid Partner Content
Better Buy: GlaxoSmithKline vs. Bristol-Myers Squibb
Feb 16 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close82.49
Today’s open82.19
Day’s range81.71 - 82.63
Volume8,870,220
Average volume (3 months)9,139,542
Market cap$209.6B
Data as of 6:30pm ET, 02/21/2020

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+10.76%
Earnings growth (next 5 years)+8.50%
Revenue growth (last year)+10.35%
P/E ratio23.0
Price/Sales5.01
Price/Book--

Competitors

 Today’s
change
Today’s
% change
NVSNovartis+0.47+0.49%
PFEPfizer-0.13-0.36%
BMYBristol-Myers Squibb+0.46+0.71%
ABBVAbbVie+0.73+0.77%
Data as of 6:30pm ET, 02/21/2020

Financials

Next reporting dateApril 28, 2020
EPS forecast (this quarter)$1.35
Annual revenue (last year)$46.8B
Annual profit (last year)$9.8B
Net profit margin21.01%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
Kenilworth, New Jersey

Forecasts